Orchestra Bio is Joining OpenAI

We're thrilled to share that Orchestra Bio is joining OpenAI to pioneer AI applications for life sciences.

Drug development is extraordinarily complex. Discovery, preclinical research, clinical trials, regulatory approvals, and manufacturing involve different teams, tools, and systems, yet bringing a new medicine to market requires integrating all of these efforts over the course of a decade or more. The stakes are enormous: roughly nine in ten drug candidates entering clinical trials never reach approval, and a single Phase III failure can cost between $800 million and $2.4 billion. Behind those numbers are patients waiting for treatments that may never arrive.

Much of the early excitement around AI in life sciences has focused on accelerating individual scientific tasks, from molecular design to medicinal chemistry and assay development. And while the progress has been remarkable, there is an equally important opportunity in addressing the operational complexity of drug development itself. Information is fragmented across teams, decisions depend on inputs from multiple functions, and delays in one part of the process can ripple across an entire program.

Orchestra Bio set out to tackle this broader challenge: building an AI-native operating layer that connects the people, information, and decisions involved in bringing new medicines to market.

The team initially focused on how to represent complex drug programs, creating a foundation for understanding the interconnected workflows and dependencies involved in developing new medicines. Over the past three years, that work has evolved into a platform where AI agents work alongside scientists and program leaders to coordinate workflows, synthesize information, and drive execution across the development lifecycle. Scientists and program leaders can devote more of their time to decisions that require their expertise, while agents take on much of the coordination and follow-through that traditionally slow programs down.

The implications go well beyond productivity gains. By connecting information and execution across the development lifecycle, AI has the potential to fundamentally change the economics of drug development, reducing the time and resources required to advance promising therapies. Even modest improvements in speed and execution can have an enormous impact. Ultimately, the greatest opportunity is to bring life-changing medicines to patients faster.

When we first met Ashoka Rajendra (CEO) during Orchestra Bio's seed raise, he had an ambitious vision for transforming how biotech companies operate with AI. What stood out immediately were the extraordinary references from former colleagues and customers. As we got to know Ashoka and the team, it became clear why they spoke so highly of him.

Ashoka and the Orchestra Bio team are among the strongest product-oriented builders we've encountered in life sciences. They combine deep domain expertise with egoless customer empathy, translating their understanding of drug development into products that address real customer needs. CTO Andy Xu has been central to that effort, bringing exceptional technical talent and a relentless iteration. 

Impressed by the team's execution and ambition, we were proud to lead Orchestra Bio's Series A last year.

Combining Orchestra Bio's deep expertise in drug development with OpenAI's frontier models, world-class research talent, and infrastructure, the team has an extraordinary opportunity to reshape how new medicines are developed and brought to market.

It has been a privilege to work alongside Ashoka, Andy, and the entire Orchestra Bio team. We're incredibly proud of what they've built and couldn't be more excited to see how they advance AI and biology at OpenAI.

‍